Large-scale testing (Phase 3)Active Not RecruitingNCT06945107
What this trial is testing
Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy
Who this might be right for
Plaque Psoriasis
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. 308